Results from the first stage of a Phase II clinical trial suggest that measuring circulating tumor DNA (ctDNA) captured in blood-based liquid biopsies may help to identify those advanced non-small ...
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback